Evidence map›Paper›PMID 32091179›Full record

ArticleJournal of the International AIDS Society2020

What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?

Diane Havlir, Shahin Lockman, Helen Ayles, Joseph Larmarange, Gabriel Chamie, Tendani Gaolathe, Collins Iwuji, Sarah Fidler, Moses Kamya, Sian Floyd and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 81 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 7 pooled it
3.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 7 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 7 countries.

Diane HavlirDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0761-3136
Shahin LockmanBrigham and Women's Hospital, Boston, MA, USA.
Helen AylesClinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Joseph LarmarangeCentre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.ORCID 0000-0001-7097-700X
Gabriel ChamieDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5860-8081
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Collins IwujiDepartment of Global Health & Infection, Brighton and Sussex Medical School, Brighton, United Kingdom.ORCID 0000-0003-2045-1717
Sarah FidlerImperial College, National Institute for Health Research Biomedical Research Center, London, United Kingdom.ORCID 0000-0003-1676-7583
Moses KamyaDepartment of Medicine, Makerere University, Kampala, Uganda.
Sian FloydDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Janet MooreDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Richard HayesDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Maya PetersenSchool of Public Health, University of California Berkeley, Berkeley, CA, USA.
Francois DabisISPED & Inserm Bordeaux Population Health UMR 1219, Univ Bordeaux, Bordeaux, France.
(Universal Test, Treat Trials) UT3 Consortium
London School of Hygiene & Tropical Medicine · GBUniversity of California, San Francisco · USBerkeley Public Health Division · USBrigham and Women's Hospital · USBrighton and Sussex Medical School · GBCenters for Disease Control and Prevention · USInfectious Diseases Research Collaboration · UGInserm · FRNational Institute for Health Research · GBUniversité de Bordeaux · FRUniversity of Botswana · BW

Funding

CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH001911Medical Research Council MR/R010161/1PEPFAR
6 · The paper itself

Abstract

introductionAchieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign. DISCUSSION: These three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a variety of home and community-based testing approaches) achieved >90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of viral suppression in SSA. Significant gains in population-level viral suppression were made in regions with both low and high baseline population viral load; however, viral suppression gains were not uniform across all sub-populations and were lower among youth. (3) UTT resulted in marked reductions in community HIV incidence when universal testing and robust linkage were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV associated mortality by 23% in the intervention versus control communities in SEARCH, a study in which mortality was comprehensively measured.

conclusionsThese trials provide strong evidence that UTT inclusive of universal testing increases population-level viral suppression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub-country level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in order to reach UNAIDS HIV elimination targets.

Indexed as

Mass ScreeningAdolescentAdultAIDS SerodiagnosisAnti-HIV AgentsBotswanaEpidemicsFemaleHIV InfectionsHumansIncidenceKenyaMalePrevalencePublic HealthSouth AfricaAnti-HIV Agentsantiretroviral therapyHIV care continuumHIV eliminationHIV preventionHIV testingpublic healthuniversal access

Identifiers

PMID32091179
PMCPMC7038879
OpenAlexW3007259777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.